Kümmel Sherko, Thomas Anke, Paepke Stefan, Schwarz Marion, Heinrich Georg, Wetzel Andrea, Elling Dirk, Kohls Andreas, Lichtenegger Werner, Blohmer Jens-Uwe
Department of Senology, University Medicine Berlin, Campus Charité Mitte, Berlin, Germany.
Acta Oncol. 2005;44(3):248-54. doi: 10.1080/02841860510029725.
Sequential, dose-dense epirubicin plus docetaxel was evaluated as primary systemic therapy for women with inoperable, locally advanced breast cancer (LABC) or inflammatory breast cancer (IBC). Patients (LABC n=27; IBC n=7) received 3 cycles of epirubicin 120 mg/m2 every 2 weeks followed by 3 cycles of docetaxel 100 mg/m2 every 2 weeks, with granulocyte colony-stimulating factor. Grade 3-4 toxicities were observed in 21 of 195 cycles (10.8%). Grade 3 anemia and leukopenia each occurred in 1% of cycles. Following chemotherapy, all patients underwent surgery. Eight patients (23.5%) had a clinical complete response and 15 (44.1%) had a partial response. In patients with IBC, median skin thickness decreased from 5.85 mm (range: 3.1-6.2 mm) to 4 mm (range: 2.7-5.1 mm) (p<0.005). Sequential, dose-dense epirubicin plus docetaxel achieved a high response rate among patients with LABC or IBC with only moderate toxicity.
序贯、剂量密集表柔比星联合多西他赛被评估作为不可手术的局部晚期乳腺癌（LABC）或炎性乳腺癌（IBC）女性患者的一线全身治疗方案。患者（LABC n = 27；IBC n = 7）每2周接受3个周期的表柔比星120 mg/m²治疗，随后每2周接受3个周期的多西他赛100 mg/m²治疗，并使用粒细胞集落刺激因子。在195个周期中有21个周期（10.8%）观察到3-4级毒性反应。3级贫血和白细胞减少各占周期数的1%。化疗后，所有患者均接受了手术。8例患者（23.5%）获得临床完全缓解，15例（44.1%）获得部分缓解。在IBC患者中，中位皮肤厚度从5.85 mm（范围：3.1 - 6.2 mm）降至4 mm（范围：2.7 - 5.1 mm）（p < 0.005）。序贯、剂量密集表柔比星联合多西他赛在LABC或IBC患者中获得了较高的缓解率，且毒性仅为中度。
